Showing 2481-2490 of 4166 results for "".
- Centricity Vision Announces New Technologies Under Development, Zeptolink and 5.5 mm Capsulotomy; Names Leonard Borrmann to Lead R&Dhttps://modernod.com/news/centricity-vision-announces-new-technologies-under-development-zeptolink-and-55-mm-capsulotomy-names-leonard-borrmann-to-lead-rd/2480783/Centricity Vision announced two product innovations under development, the Zeptolink platform and Zepto 5.5 mm capsulotomy technology. The company has also appointed Leonard Borrmann, PharmD, to lead research and development. "The Zepto technology is elevating the precisi
- Notal Vision Announces Publication First Prospective Longitudinal Pilot Study of Daily Self-Imaging With Patient-Operated Home OCT in Wet AMD Patientshttps://modernod.com/news/notal-vision-announces-publication-first-prospective-longitudinal-pilot-study-of-daily-self-imaging-with-patient-operated-home-oct-in-wet-amd-patients/2479365/Notal Vision announced that results from the first prospective longitudinal pilot study of daily, home-based self-imaging with their investigational, patient-operated Home OCT for wet age-related macular degeneration (AMD) patients have been published in
- In Recognition of World Sight Day, Lighthouse Guild Receives Donation from Bausch Foundation to Support Computer Training for People with Vision Losshttps://modernod.com/news/in-recognition-of-world-sight-day-lighthouse-guild-receives-donation-from-bausch-foundation-to-support-computer-training-for-people-with-vision-loss/2478391/Lighthouse Guild has received a $10,000 gift from Bausch Foundation to purchase new computers to train people with vision loss for work, school and daily living. The computers will be used at Lighthouse Guild’s Assistive Technology Training Center in Manhattan. Assistive technology include
- Ocuphire Announces Peer-Reviewed Publication for Nyxol and Strategic Partnership with ASOAhttps://modernod.com/news/ocuphire-announces-peer-reviewed-publication-for-nyxol-and-strategic-partnership-with-asoa/2481215/Ocuphire Pharma announced that the positive results in night vision disturbances (NVD) patients from its earlier and first phase 2 study evaluating the safety and efficacy of phentolamine mesylate eye drops (Nyxol) have been peer-reviewed and published in BMC Ophthalmology. <
- Ciliatech Presents New Concept in Glaucoma Implants, First to Bypass Opening Anterior Eye Chamberhttps://modernod.com/news/ciliatech-presents-new-concept-in-glaucoma-implants-first-to-bypass-opening-anterior-eye-chamber/2481085/Ciliatech, which is developing a new class of implant to treat glaucoma durably named
- Aviceda Announces Additional Members to its Clinical Advisory Board to Support its Clinical Development Strategy in Ophthalmologyhttps://modernod.com/news/aviceda-announces-additional-members-to-its-clinical-advisory-board-to-support-its-clinical-development-strategy-in-ophthalmology/2481232/Aviceda Therapeutics, a clinical-stage biotech company focused on developing the next generation of immuno-modulators, announced the addition of ophthalmic key opinion leaders to its clinical advisory board. The new additional Aviceda Clinical Advisory Board members are:
- Hoya Presents New Clinical Evidence on Myopia Management and Launch of visuReal MoveAI Kids Modulehttps://modernod.com/news/hoya-presents-new-clinical-evidence-on-myopia-management-and-launch-of-visureal-moveai-kids-module/2482810/Hoya Vision Care presented its latest clinical evidence at the 16th Annual European Academy of Optometry and Optics (EAOO) conference in Ljubljana, Slovenia. The company also unveiled its new visuReal MoveAI Kids Module, an AI-powered video centration syste
- Salvat Laboratories Presents Phase 3 Clinical Trials Results of Clobetasol Nanoemulsion for Treating Inflammation and Pain After Ocular Surgeryhttps://modernod.com/news/salvat-laboratories-presents-phase-3-clinical-trials-results-of-clobetasol-nanoemulsion-for-treating-inflammation-and-pain-after-ocular-surgery/2481604/Salvat Laboratories announced the results of phase 3 clinical trials of its ophthalmic corticosteroid at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting in New Orleans. The studies’ global coordinator, Andrew Schwartz, MD, presented a poster outlinin
- RG6501 (OpRegen) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in GAhttps://modernod.com/news/rg6501-opregen-phase-12a-clinical-results-support-the-potential-for-opregen-to-slow-stop-or-reverse-disease-progression-in-ga/2481569/Lineage Cell Therapeutics announced that results from imaging analyses of structural changes and visual data from a phase 1/2a clinical study of RG6501 (OpRegen), were presented at the 2023 Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2023). The presentation
- Atsena Therapeutics Announces 6-Month Data from Phase 1/2 Clinical Trial of ATSN-101 to be Presented at ARVOhttps://modernod.com/news/atsena-therapeutics-announces-6-month-data-from-phase-12-clinical-trial-of-atsn-101-to-be-presented-at-arvo/2481523/Atsena Therapeutics announced that 6-month safety and efficacy data from the ongoing phase 1/2 clinical trial of ATSN-101 in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D (LCA1) will be presented at the Association for Research in Vision and Ophthalmol